Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

DSIPvsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/36 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
DSIP
Sleep modulator · Anti-stress
100–200 mcgPer doseSchneider 1986
HumanMechanisticSchneider 1986
HoursHalf-life (est)
SQ · Pre-sleep · Daily during cycle
Testagen
Bioregulator Peptide · Khavinson School
Lys-Glu-Asp-GlySequenceFedoreyeva 2011
NuclearLocalizationFedoreyeva 2011
TesticularTissue target
SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter
DSIP
Testagen
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
Testicular tissue; proposed nuclear DNA interaction
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
Unknown — no HPG axis data
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development

02Dosage Protocols

Parameter
DSIP
Testagen
Standard dose
100–200 mcg SQ pre-sleepSchneider 1986
Frequency
Once daily, pre-sleep
Once daily or alternate days
Lower / starter dose
50 mcg pre-sleep
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
Animal mechanistic / in vitro onlyFedoreyeva 2011
Duration
8–12 weeks per cycle
Reconstitution
Bacteriostatic water
Sterile water or bacteriostatic saline
Timing
30–60 min pre-sleep
Half-life
Short plasma; CNS effects last hours
Unknown — likely minutes (short peptide)
Typical protocol (anecdotal)
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
Subcutaneous

04Side Effects & Safety

Parameter
DSIP
Testagen
Injection site reaction
Mild irritation
Drowsiness
Expected effect (intentional)
Vivid dreams
Anecdotally reported
Long-term safety
Limited modern RCT data
Unknown — no long-term studies
Pregnancy / OB
Avoid
Injection site reactions
Erythema, mild irritation (potential)
Systemic effects
Unknown — no human safety data
Hormonal impact
No published data on testosterone, LH, FSH effects
Absolute Contraindications
DSIP
  • ·Pregnancy / breastfeeding
  • ·Concurrent CNS-depressant therapy without supervision
Testagen
  • ·Active testicular malignancy
Relative Contraindications
DSIP
  • ·Severe sleep apnoea (untreated)
  • ·Concurrent benzodiazepine / opioid use
Testagen
  • ·Hormone-sensitive cancers (no data; theoretical caution)
  • ·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter
DSIP
Testagen
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Injection site
SQ — abdomen. Rotate sites.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
30–60 min pre-sleep.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Needle
29–31G insulin syringe.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.